Feed CLYYF
Summary
40 / 100 · Bulios Score
Valuation 50Growth 0Profitability 40Quality 45Debt 54Stability 57
What speaks for it
- Out of every 100 EUR of revenue, 47,202 EUR is left as net profit.
- It holds more cash than debt: 120.8K € against 25.0K €.
- You pay 3.6 EUR for 1 EUR of yearly profit, little for its sector.
What to watch
- It reports a profit, yet spends more cash than it brings in.
- Its last loss-making year was 2 years ago.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedP/E today 3.6
Biotechnology industry median
Today you pay 3.6 EUR for 1 EUR of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (EUR)
20212022202320242025
Diluted EPS (EUR)
20212022202320242025
Revenue grew by 33% a year over 5 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 EUR of revenue goes
- Cost of sales -29,707 EUR
- Research and development 19,115 EUR
- Sales and administration 78,535 EUR
- Taxes and other -115,065 EUR
- Net profit 47,202 EUR
Net profit, industry median (Biotechnology) -7.1 EUR
Out of every 100 EUR of revenue, 47,202 EUR is left as net profit.
Profitability in detailIs it financially healthy?
YesCash and short-term investments 120.8K €
Debt 25.0K €
Free cash flow over 12 months -7.48M €
Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 2
- Hold 2
- Sell 0
No analyst has published a price target.
50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.